Bharat Biotech’s Covaxin is 81% effective in trials

Bharat Biotech’s Covaxin is 81% effective in trials

Bharat Biotech on Wednesday announced the first interim analysis of Covaxin, which shows the efficacy of the Covid-19 vaccine to be at 81 per cent.The Hyderabad-based vaccine maker said whole virion inactivated Covid-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial.The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research (ICMR).